 Amryt Pharma PLC NASDAQ:AMYT, LON:AMYT said has completed the rolling submission process that it hopes will end with the fast-track sign-off by the US Food Drug Administration for its gel to treat a rare and distressing skin disease. Its new drug application NDA for Oleogel-S10 could be reviewed in just six months under an expedited protocol that aims to bring through new products for rare ailments such as junctional and dystrophic epidermolysis bullosa EB. 